We make innovative vaccines and specialty medicines to prevent and treat disease. Our R&D focuses on the science of the immune system, human genetics and advanced technologies.
Our R&D focus is on four therapeutic areas: infectious diseases, HIV, oncology, and immunology.
Behind the science
Discover how we're getting ahead
Eosinophils could be holding the missing link between symptoms, diagnosis and treatment
Time for a change: personalising asthma treatment
Unlocking the power of the immune system to get ahead of hepatitis B
Tackling tomorrow’s health challenges today
How vaccine science can help tackle antimicrobial resistance
The 40 year fight against HIV
How the next generation of immuno-oncology could help us get ahead of cancer
1.4 million reasons to get ahead of gynaecologic cancers
Digital twin: using advanced technology to accelerate vaccine development
What if remission were the target of lupus care?
Life at GSK
How we help people thrive
Diversity, equity and inclusion
Positively impacting society and the planet
Pricing and access
We are making our products affordable and available to more people around the world through responsible pricing, strategic access programmes and partnerships.
Global health and health security
We are committed to using our science, our partnerships, and the knowledge we’ve gained from addressing the world’s biggest health challenges to improve health globally.
Diversity, equity and inclusion
Our work supports the health of all kinds of people. To meet our diverse patients' needs better, we need diversity in our clinical trials and to support our own people to thrive as part of an inclusive team.
We are working towards a net zero impact on climate and a net positive impact on nature by 2030, across our full value chain.
Ensuring the quality, safety and reliable supply of our products is critical to our purpose of uniting science, talent and technology to get ahead of disease together.
In the spotlight
GSK on social
87% of people with #lupus who responded to a survey by the @WorldLupusFed reported at least one organ or organ system was affected by the disease. We’re working to lower this figure. Read about advances in lupus management 👇
Congratulations to our CEO Emma Walmsley and all of the other accomplished women named to @FortuneMagazine’s list of the 50 most powerful women.
At the Institute of Molecular and Computational Medicine (IMCM) at Oxford, we’re bringing together patients, scientists and technology to outsmart complex neurological diseases. #AheadTogether
Did you know that bacterial meningitis and neonatal sepsis combined are the 2nd biggest infectious killers of children globally?
How many people are expected to be aged 60 and above by 2030?
The @ABPI_UK has today published its latest survey on the links between industry and academia, showing how the pharmaceutical industry is supporting student training and research placements. Hear from our own Malcolm Skingle on the value of academia-industry collaboration. twitter.com/ABPI_UK/status…
We're excited to be in Belfast tomorrow for the #RSV2022 symposium. We look forward to discussing the burden of #RSV and share our expertise on risk factors of viral respiratory disease in adults. #GSKproud #UNIDOP22